FindTrial
Sign In

Performances of controlled Attenuation Parameter (CAP) and stiffness measurement assessed by FIBROSCAN for the diagnosis of liver steatosis and liver fibrosis

Performances of controlled Attenuation Parameter (CAP) assessed by FIBROSCAN for the diagnosis of liver steatosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-13003983
Enrollment
Unknown
Registered
2013-05-13
Start date
2012-11-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver Disease

Interventions

Gold Standard:
Index test:

Sponsors

Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 65 years, Male and Female; 2.Eligible Liver biopsy samples are available within two week; 3.Patient is able to give informed consent.

Exclusion criteria

Exclusion criteria: 1. Unable or unwilling to provide informed consent; 2. Malignant tumor or other terminal disease; 3. ALT > 10 NUL; 4. Autoimmune liver disease?Hepatobiliary parasitology; 5. Patients with non compensated cirrhosis ( especially with ascites); 6. BMI>30; 7. Patients with implantable medical device such as pacemaker; 8. Patients with wound in right upper quadrant; 9. Pregnant women.

Design outcomes

Primary

MeasureTime frame
liver stiffness;Controlled Attenuation Parameter;Liver Biopsy;—

Countries

China

Contacts

Public ContactJiangao Fan

Department of Gastroenterology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine

fanjiangao@gmail.com+86 13818868519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 3, 2026